ZURICH, March 21 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX) said the European Commission approved its multiple sclerosis pill Gilenya, a potential blockbuster that should help it cope with price pressures and competition from generics.
ZURICH, March 21 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX) said the European Commission approved its multiple sclerosis pill Gilenya, a potential blockbuster that should help it cope with price pressures and competition from generics.
